Anavex Life Sciences Corp.
HealthcareNASDAQ:AVXL · NASDAQ Global Select
+$0.00 today
Vol 1.20M · Avg 1.38M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $131.7M |
| Receivables | $844.0K |
| Other Current | $396.0K |
| Total Current Assets | $133.0M |
| Total Assets | $133.0M |
Analysis
Selected assets total $133.0M for Latest. The largest visible component is Cash & Equivalents at $131.7M, about 99.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102.6M -22.4% | $132.2M -12.5% | $151.0M +1.3% | $149.2M -1.9% | $152.1M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $809.0K -67.0% | $2.4M -9.6% | $2.7M -15.2% | $3.2M -65.1% | $9.1M | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 -100.0% | $16.4K | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $429.0K -53.9% | $931.0K +42.6% | $653.0K +402986.4% | $162 +101.0% | -$16.4K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $103.8M -23.4% | $135.6M -12.2% | $154.4M +1.1% | $152.7M -5.5% | $161.6M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $0 | $0 | $0 | $0 | $0 | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $0 | $0 -100.0% | $3.4M -99.9% | $3.5B +21672628.4% | $16.4K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $0 | $0 -100.0% | $3.4M -99.9% | $3.5B +21672628.4% | $16.4K | -$15.3B | $14.8B | $11.3B |
| Total Assets | $103.8M -23.4% | $135.6M -12.2% | $154.4M +1.1% | $152.7M -5.5% | $161.6M | $13.3B | $11.9B | $10.6B |
| Account Payables | $4.2M -55.9% | $9.6M +122.7% | $4.3M +13.0% | $3.8M -19.3% | $4.7M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $805.0K -4.4% | $842.0K | $0 -100.0% | $443.8K +0.0% | $443.8K | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $1.6M +2.3% | $1.5M -77.7% | $6.9M +14578823.4% | -$47 | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $8.9M -41.5% | $15.3M +22.1% | $12.5M +22.7% | $10.2M -5.4% | $10.8M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $8.9M -41.5% | $15.3M +22.1% | $12.5M +22.7% | $10.2M -5.4% | $10.8M | $14.7B | $3.7B | $9.6B |
| Common Stock | $87.0K +2.4% | $85.0K +3.7% | $82.0K +5.2% | $77.9K +2.7% | $75.9K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$382.4M -13.8% | -$336.1M -14.7% | -$293.1M -19.3% | -$245.6M -24.3% | -$197.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $94.9M -21.1% | $120.3M -15.2% | $141.9M -0.4% | $142.5M -5.5% | $150.8M | $9.1B | $7.7B | $3.3B |
| Total Debt | $0 | $0 | $0 | $0 | $0 | $724.2M | $410.6M | $399.4M |
| Net Debt | -$102.6M +22.4% | -$132.2M +12.5% | -$151.0M -1.3% | -$149.2M +1.9% | -$152.1M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
Absci Corporation
NASDAQ:ABSI
$1.06B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Astria Therapeutics, Inc.
ATXS
$718.13M
Valneva SE
NASDAQ:VALN
$507.78M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$484.08M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does AVXL have?
Anavex Life Sciences Corp. (AVXL) reported $102.58M in cash and equivalents in fiscal 2025.
How much debt does AVXL carry?
Anavex Life Sciences Corp. (AVXL) reported $0.00 of total debt, with net debt of -$102,577,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.